论文部分内容阅读
目的探讨艾迪注射液联合化疗对晚期非小细胞肺癌(NSCLC)患者的近期疗效及对血清中血管内皮生长因子C(VEGF-C)和细胞角蛋白19片段(CYFR21-1)水平的影响。方法 60例晚期NSCLC患者随机分为观察组(n=30)和对照组(n=30),观察组给予艾迪注射液联合吉西他滨+顺铂化疗方案,对照组给予吉西他滨+顺铂化疗方案;治疗2个周期后观察2组近期疗效及血清VEGF-C和CYFR21-1水平的变化。结果治疗2个周期后,观察组有效率50.0%高于对照组的43.3%,但2组比较差异无统计学意义(P>0.05);观察组临床受益率80.0%明显高于对照组的60.0%,2组比较差异有统计学意义(P<0.05)。2组治疗后血清VEGF-C和CYFR21-1水平均较治疗前明显降低(P<0.05,P<0.01);治疗后观察组血清VEGF-C和CYFR21-1水平明显低于对照组,差异有统计学意义(P<0.05)。结论艾迪注射液联合化疗可有效提高晚期NSCLC患者临床受益率,并显著降低血清VEGF-C和CYFR21-1水平,从而提高化疗效果。值得临床推广应用。
Objective To investigate the short-term efficacy of Aidi injection combined with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and the effects on the levels of vascular endothelial growth factor C (VEGF-C) and cytokeratin 19 (CYFR21-1) in serum. Methods Sixty patients with advanced NSCLC were randomly divided into observation group (n=30) and control group (n=30). The observation group was given Aidi injection combined with chemotherapy regimen of gemcitabine plus cisplatin, and the control group was given chemotherapy regimen of gemcitabine plus cisplatin; After 2 cycles of treatment, the curative effect of the two groups and the changes of serum VEGF-C and CYFR21-1 levels were observed. Results After two cycles of treatment, the observation group’s effective rate was 50.0% higher than the control group’s 43.3%, but there was no significant difference between the two groups (P>0.05). The observation group’s clinical benefit rate was 80.0% was significantly higher than the control group’s 60.0. The difference between the two groups was statistically significant (P<0.05). The serum VEGF-C and CYFR21-1 levels after treatment in both groups were significantly lower than before treatment (P<0.05, P<0.01); after treatment, serum VEGF-C and CYFR21-1 levels were significantly lower in the observation group than in the control group. Statistical significance (P<0.05). Conclusion Aidi injection combined with chemotherapy can effectively improve the clinical benefit rate of patients with advanced NSCLC, and significantly reduce serum VEGF-C and CYFR21-1 levels, thereby increasing the effect of chemotherapy. Worthy of clinical application.